Pasireotide: an injectable medical therapy for the treatment of Cushing’s disease

Document first published:
Page updated:
Topic:
,
Publication type:

Pasireotide is recommended to be available as a routine commissioning treatment option for Cushing’s disease within the criteria set out in this document.

Document

Clinical commissioning policy - pasireotide: an injectable medical therapy for the treatment of Cushing’s disease

Clinical commissioning policy - pasireotide: an injectable medical therapy for the treatment of Cushing’s disease

  • PDF
  • 199 KB
  • 9 pages

Summary

Published December 2016 and updated July 2026.